Cullinan Oncology(US:CGEM)2021-04-13 20:17Company Overview - Cullinan has a well-capitalized position with approximately $490 million in cash and investments as of December 31, 2020[6] - The company employs a differentiated hub-and-spoke model with a robust pipeline of 7 novel oncology programs[6] Clinical Programs - CLN-081 (Pearl): A selective EGFR inhibitor targeting Exon 20 insertion mutant NSCLC, with Phase 2a expansion initiated in February 2021 and plans for a potentially registrational Phase 2b study in 2021[8, 10, 18] - Preliminary data for CLN-081 shows promising responses across several mutations, with one DLT observed at 150 mg BID as of November 10, 2020[15, 18] - CLN-619 (MICA): An anti-MICA/B IgG1 antibody with IND submission anticipated in 2Q21, showing single-agent tumor regression in a PLC/PRF/5 liver cancer model[8, 24] - CLN-049 (Florentine): A FLT3 x CD3 bispecific antibody for r/r AML, with program updates expected in 2021[8] - CLN-978 (NexGem): A CD19 and CD3 trispecific antibody for B-cell ALL, with IND submission planned for 2022[8] - CLN-617 (Amber): An IL2 x IL12 x CBD therapeutic for pan-cancer, with IND submission anticipated in 2022[8]